Literature DB >> 10663969

Hepatitis C virus infection and myositis: a polymerase chain reaction study.

M Villanova1, C Caudai, P Sabatelli, P Toti, A Malandrini, P Luzi, N M Maraldi, P E Valensin, L Merlini.   

Abstract

Muscle biopsy tissue from a patient with chronic hepatitis, who was hepatitis C virus (HCV) positive and showed slight weakness of the right arm and leg associated with increased serum creatine kinase levels, was studied using immunocytochemical and polymerase chain reaction (PCR) techniques. Muscle biopsy showed changes compatible with an inflammatory myopathy. Immunohistochemical studies included the use of monoclonal antibodies against human T lymphocytes, macrophages, immunoglobulins, major histocompatibility complex class I molecules (MHC-I), and the neoantigens of the terminal C5b-9 complement membrane attack complex (MAC). In addition to confirming the potential importance of cytotoxic T cells and MHC-I antigen expression in inducing muscle pathology, we demonstrated MAC deposition and the presence of HCV-RNA in the muscle of our patient, suggesting that direct involvement of the virus leading to complement activation might be important in inducing muscle damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10663969     DOI: 10.1007/pl00007437

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  3 in total

1.  Paraspinal Myositis in Patients with COVID-19 Infection.

Authors:  W A Mehan; B C Yoon; M Lang; M D Li; S Rincon; K Buch
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

Review 2.  HCV-related nervous system disorders.

Authors:  Salvatore Monaco; Sergio Ferrari; Alberto Gajofatto; Gianluigi Zanusso; Sara Mariotto
Journal:  Clin Dev Immunol       Date:  2012-07-30

3.  Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).

Authors:  Cordelia Manickam; Lynn Wachtman; Amanda J Martinot; Luis D Giavedoni; R Keith Reeves
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.